Last €1.62 EUR
Change Today -0.01 / -0.61%
Volume 390.0
As of 7:39 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (AQL) Snapshot

Open
€1.62
Previous Close
€1.63
Day High
€1.68
Day Low
€1.62
52 Week High
02/26/15 - €1.73
52 Week Low
10/24/14 - €0.80
Market Cap
101.8M
Average Volume 10 Days
4.1K
EPS TTM
--
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (AQL)

arqule inc (AQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (AQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover therapeutic compounds that selectively inhibit certain kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

46 Employees
Last Reported Date: 11/10/14
Founded in 1993

arqule inc (AQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Chief Operating Officer, Principal...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.3K
Compensation as of Fiscal Year 2013.

arqule inc (AQL) Key Developments

ArQule Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:00 AM

ArQule Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Paolo Pucci, Chief Executive Officer and Director.

ArQule Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:00 AM

ArQule Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:00 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Brian Schwartz, Chief Medical Officer and Senior Vice President of Clinical & Regulatory Affairs, Paolo Pucci, Chief Executive Officer and Director.

ArQule, Inc. Announces Agreement with National Human Genome Research Institute for Providing for the Clinical Development of ARQ 092

ArQule Inc. announced an agreement with the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system. The NIH Proteus syndrome team is led by researchers who originally discovered the somatic single (point) mutation in the AKT 1 oncogene that causes Proteus syndrome. On that basis, the NIH entered into a collaboration with ArQule focused on pre-clinical testing of ARQ 092. Results from that pre-clinical research recently presented by the NIH team at the 2014 meeting of the American Society of Human Genetics (ASHG, Abstract # 2180M) demonstrate that treatment with ARQ 092 caused a rapid shutdown of AKT signaling and a reduction in the viability of Proteus syndrome cells taken from patients compared to untreated diseased cells. These findings represent pre-clinical proof-of-concept for advancement of ARQ 092 into clinical testing in this indication.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQL:GR €1.62 EUR -0.01

AQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.17 USD -0.08
CrystalGenomics Inc 12,750 KRW +200.00
Curis Inc $3.08 USD 0.00
Cytokinetics Inc $7.87 USD +0.16
Rigel Pharmaceuticals Inc $3.11 USD +0.12
View Industry Companies
 

Industry Analysis

AQL

Industry Average

Valuation AQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.